Predict your next investment

Corporation
HEALTHCARE | Biotechnology
editasmedicine.com

See what CB Insights has to offer

Founded Year

2013

Stage

IPO | IPO

Total Raised

$163M

Date of IPO

2/3/2016

Market Cap

2.14B

Stock Price

32.66

About Editas Medicine

Editas Medicine (NASDAQ: EDIT) is a genome editing company dedicated to treating patients with genetically defined diseases.

Editas Medicine Headquarter Location

11 Hurley Street

Cambridge, Massachusetts, 02141,

United States

617-401-9000

Latest Editas Medicine News

Horizon (HZNP) Gets Positive CHMP Opinion for Uplizna in NMOSD

Nov 15, 2021

The CHMP gives a positive opinion on, and recommends approval to Horizon's (HZNP) Uplizna for treating adult patients with neuromyelitis optica spectrum disorder. This story originally appeared on Zacks Horizon Therapeutics Public Limited Company HZNP announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion on, and has recommended marketing authorization to Uplizna (inebilizumab) as a monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorder (“NMOSD”) who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+). - Zacks The opinion will now be reviewed by the European Commission, which has already granted orphan designation to Uplizna for the given indication. The positive CHMP opinion was based on data from the N-MOmentum program. Data from the program showed that treatment with Uplizna as a monotherapy reduces the risk of relapse by 77% versus placebo in AQP4-IgG+NMOSD adult patients. Shares of Horizon have rallied 50.2% so far this year against the industry ’s decline of 13.9%. Image Source: Zacks Investment Research We note that in June 2020, the FDA approved Uplizna for adult patients with AQP4-IgG+ NMOSD in order to reduce the risk of attacks. Uplizna is also approved in Japan for the same indication. Per the company, it is the only approved NMOSD therapy to demonstrate a clinically relevant and durable effect on delaying worsening of disability, with a significant reduction in hospitalization in the United States. The FDA has granted a Breakthrough Therapy and Orphan Drug designation to Uplizna. The drug generated sales worth $18.7 million in the third quarter of 2021. Several studies on Uplizna are currently ongoing for different indications. Horizon is currently evaluating Uplizna in a placebo-controlled phase III study for treating patients with myasthenia gravis, a chronic, rare, autoimmune neuromuscular disease. Another phase III study is investigating Uplizna in patients with IgG4-related disease. A potential label expansion for any of the above indications should boost Uplizna sales in the days ahead. Zacks Rank & Stocks to Consider Horizon currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Galera Therapeutics, Inc. GRTX , vTv Therapeutics Inc. VTVT and Editas Medicine, Inc. EDIT , all carrying a Zacks Rank #2 (Buy) at present. You can see  the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here . Galera Therapeutics’ loss per share estimates have narrowed 19.5% for 2021 and 32.3% for 2022, over the past 60 days. Earnings of Galera Therapeutics have surpassed estimates in only one of the trailing four quarters, and missed the same on the other three occasions. vTv Therapeutics’ loss per share estimates have narrowed 21.7% for 2021 and 2.9% for 2022, over the past 60 days. vTv Therapeutics’ earnings have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. Editas Medicine’s loss per share estimates have narrowed 11.9% for 2021 and 4.1% for 2022, over the past 60 days. Editas Medicine’s earnings have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Editas Medicine

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Editas Medicine in 1 CB Insights research brief, most recently on Aug 31, 2021.

Article Thumbnail

Aug 31, 2021

What Is CRISPR?

Expert Collections containing Editas Medicine

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Editas Medicine is included in 3 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

235 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Editas Medicine Patents

Editas Medicine has filed 66 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Molecular biology
  • Genetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/25/2016

11/23/2021

Small nuclear RNA, Molecular biology, Biotechnology, Genetic engineering, Genetics

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/25/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/23/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Small nuclear RNA, Molecular biology, Biotechnology, Genetic engineering, Genetics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Editas Medicine Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Editas Medicine Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.